8 citations
,
October 2018 in “The Journal of Allergy and Clinical Immunology”
Activating the Nrf2 pathway reduces inflammation and cell activation in human hair follicles, suggesting a potential treatment for certain hair loss conditions.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
Treatments for hair loss, including microneedling (dermarolling and dermapen) and the use of minoxidil, finasteride, and RU58841. It provides detailed information about cost and usage of the various treatments, as well as potential side effects.
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.
A person with hair loss since COVID-19 is considering treatments like finasteride and minoxidil but is hesitant due to potential side effects. Suggestions include visiting a dermatologist, using a ketoconazole shampoo, and considering that post-COVID hair loss might be an autoimmune response.
A user is concerned about the legitimacy of a hair growth serum called Lavdik, which they ordered after seeing an ad for Jemros. The product contains ginger extract, ginseng extract, fleece flower root, grape seed oil, glycerol, carbomer, propylene glycol, and rosemary oil, and the user is unsure if it is effective or a scam.